In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California Institute of Technology

www.caltech.edu

Latest From California Institute of Technology

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals... 
Deals Financing

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
Research & Development Deals

Venture Funding Deals: $688.8m In Financings From Avitide To Zai Lab

June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.

Financing Deals

Science Matters: Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders

New research offers mechanistic proof of signaling between gut and brain in Parkinson’s disease, showing that introducing an altered microbiome from PD patients into a mouse model can recreate the motor symptoms of the disease.

Neurology Innovation
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register